Ultragenyx Pharmaceutical (RARE) Stock Forecast & Price Target

Ultragenyx Pharmaceutical is a leading orphan-drug company with a diversified rare-disease portfolio, including Crysvita, Dojolvi, and Mepsevii, plus a deep gene-therapy pipeline spanning at least six indications. Its bullish case is anchored by Crysvita’s $2B+ global sales potential, a meaningful profit-sharing arrangement on that asset, and the possibility that the commercial business alone still implies >80% upside while the market appears to assign limited value to the pipeline. Additional support comes from ~$400M in potential non-dilutive PRV-related capital, high expected penetration of the prevalent pool, and management’s commitment to significant expense reductions with profitability targeted for FY27.

Ultragenyx Pharmaceutical is facing a deteriorating fundamental outlook because the failed ASPIRE Phase 3 trial for GTX-102 eliminates a major growth driver, removes an estimated $1.7 billion in peak sales from the model, and contributes to a sharp reduction in valuation assumptions. The company also remains exposed to lower-than-expected revenues from its base business, competitive pressure across lead indications, and the risk that patients and payors resist switching to or reimbursing expensive gene therapies amid heightened regulatory scrutiny and safety concerns. With clinical, commercial, and regulatory uncertainty still high, and FY30 non-GAAP net income now modeled at just $66 million, execution across the remaining portfolio looks increasingly fragile.